Iluvien (Fluocinolone Acetonide)

Fluocinolone acetonide is a synthetic glucocorticoid that binds to glucocorticoid receptors inside ocular cells. This binding alters gene expression, leading to reduced production of inflammatory cytokines and angiogenic factors, which in turn decreases inflammation and vascular leakage within the retina.

The dosing regimen for Iluvien is set by the prescribing ophthalmologist based on the severity of the disease, prior treatment history, and individual patient factors. The implant delivers a continuous low‑dose of fluocinolone acetonide over several months, and the clinician decides when, if ever, a replacement is needed.

Safety data for Iluvien in pregnancy and lactation are limited. Because systemic exposure is possible, the product should be used only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient before prescribing.

To order Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iluvien provides a longer‑acting release of fluocinolone acetonide, lasting up to 36 months, whereas Ozurdex (dexamethasone) typically releases drug for up to six months and may require repeated injections. Both are corticosteroids, but Iluvien’s extended duration can reduce the frequency of procedures, while the safety profile regarding intra‑ocular pressure and cataract formation remains comparable.

Iluvien should be stored at ambient temperature, below 25 °C, in its original sealed packaging. The device must be protected from moisture, direct sunlight, and physical shock. Do not expose the implant to extreme temperatures or freeze it, as this could compromise its integrity.

Iluvien is implanted by a qualified ophthalmic surgeon using a specialized applicator. The implant is inserted through the pars plana into the vitreous cavity of the eye under sterile conditions. The procedure is performed in an operating‑room setting and typically requires local anesthesia.

The most serious risks include significant elevation of intra‑ocular pressure that may lead to glaucoma, development or progression of cataracts, and rare but vision‑threatening events such as endophthalmitis, retinal detachment, or implant migration. Patients should be monitored closely for these complications throughout treatment.

Iluvien is contraindicated in patients with active ocular infection, known hypersensitivity to fluocinolone acetonide or any component of the implant, and those who have had recent intra‑ocular surgery that has not fully healed. Caution is also advised for individuals with uncontrolled glaucoma or a history of steroid‑responsive intra‑ocular pressure rise.